Vera Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:VERA   3:59:50 PM EDT
14.92
+0.03 (+0.20%)
Earnings Announcements

Vera Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results

Published: 03/24/2022 10:40 GMT
Vera Therapeutics Inc - Ordinary Shares - Class A (VERA) - Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results.
Q4 Loss per Share $0.79.
For Three Months Ended December 31, 2021, Company Reported a Net Loss of $16.8 Million, Or a Net Loss per Diluted Share of $0.79.
Reported Approximately $79.7 Million in Cash and Cash Equivalents As of December 31, 2021.
Phase 2b Origin Clinical Trial of Atacicept on Track, Topline Data Expected Q4 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.66

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.76

More details on our Analysts Page.